Literature DB >> 21871868

Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.

Yoshiki Katsumi1, Tomoko Iehara, Mitsuru Miyachi, Shigeki Yagyu, Satoko Tsubai-Shimizu, Ken Kikuchi, Shinichi Tamura, Yasumichi Kuwahara, Kunihiko Tsuchiya, Hiroshi Kuroda, Tohru Sugimoto, Peter J Houghton, Hajime Hosoi.   

Abstract

Malignant rhabdoid tumor (MRT) is a rare and highly aggressive neoplasm of young children. MRT is characterized by inactivation of integrase interactor 1 (INI1). Cyclin-dependent kinase 4 (CDK4), which acts downstream of INI1, is required for the proliferation of MRT cells. Here we investigated the effects of PD 0332991 (PD), a potent inhibitor of CDK4, against five human MRT cell lines (MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS, KP-MRT-YM). In all of the cell lines except KP-MRT-YM, PD inhibited cell proliferation >50%, (IC(50) values 0.01 to 0.6 μM) by WST-8 assay, and induced G1-phase cell cycle arrest, as shown by flow cytometry and BrdU incorporation assay. The sensitivity of the MRT cell lines to PD was inversely correlated with p16 expression (r=0.951). KP-MRT-YM cells overexpress p16 and were resistant to the growth inhibitory effect of PD. Small interfering RNA against p16 significantly increased the sensitivity of KP-MRT-YM cells to PD (p<0.05). These results suggest that p16 expression in MRT could be used to predict its sensitivity to PD. PD may be an attractive agent for patients with MRT whose tumors express low levels of p16.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871868      PMCID: PMC3214763          DOI: 10.1016/j.bbrc.2011.08.047

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

Authors:  J L Dean; C Thangavel; A K McClendon; C A Reed; E S Knudsen
Journal:  Oncogene       Date:  2010-05-17       Impact factor: 9.867

2.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Authors:  Karine Michaud; David A Solomon; Eric Oermann; Jung-Sik Kim; Wei-Zhu Zhong; Michael D Prados; Tomoko Ozawa; C David James; Todd Waldman
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

3.  Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism.

Authors:  Yasumichi Kuwahara; Aubri Charboneau; Erik S Knudsen; Bernard E Weissman
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

4.  Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.

Authors:  Yoshiki Katsumi; Yasumichi Kuwahara; Shinichi Tamura; Ken Kikuchi; Osamu Otabe; Kunihiko Tsuchiya; Tomoko Iehara; Hiroshi Kuroda; Hajime Hosoi; Tohru Sugimoto
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

5.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Authors:  Richard S Finn; Judy Dering; Dylan Conklin; Ondrej Kalous; David J Cohen; Amrita J Desai; Charles Ginther; Mohammad Atefi; Isan Chen; Camilla Fowst; Gerret Los; Dennis J Slamon
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

6.  Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo.

Authors:  Yasumichi Kuwahara; Hajime Hosoi; Shinya Osone; Masakazu Kita; Tomoko Iehara; Hiroshi Kuroda; Tohru Sugimoto
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

7.  Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5.

Authors:  Zhi-Kai Zhang; Kelvin P Davies; Jeffrey Allen; Liang Zhu; Richard G Pestell; David Zagzag; Ganjam V Kalpana
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

8.  SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus.

Authors:  Sima Kheradmand Kia; Marcin M Gorski; Stavros Giannakopoulos; C Peter Verrijzer
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

9.  P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells.

Authors:  Igor Oruetxebarria; Francesca Venturini; Tuija Kekarainen; Ada Houweling; Lobke M P Zuijderduijn; Adone Mohd-Sarip; Robert G J Vries; Rob C Hoeben; C Peter Verrijzer
Journal:  J Biol Chem       Date:  2003-11-06       Impact factor: 5.157

10.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Authors:  I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre
Journal:  Nature       Date:  1998-07-09       Impact factor: 49.962

View more
  11 in total

Review 1.  Targeting CDK6 in cancer: State of the art and new insights.

Authors:  Solomon Tadesse; Mingfeng Yu; Malika Kumarasiri; Bich Thuy Le; Shudong Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.

Authors:  Julia A Elvin; Laurie M Gay; Rita Ort; Joseph Shuluk; Jennifer Long; Lauren Shelley; Ronald Lee; Zachary R Chalmers; Garrett M Frampton; Siraj M Ali; Alexa B Schrock; Vincent A Miller; Philip J Stephens; Jeffrey S Ross; Richard Frank
Journal:  Oncologist       Date:  2017-03-10

3.  Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.

Authors:  Carl E Allen; Theodore W Laetsch; Rajen Mody; Meredith S Irwin; Megan S Lim; Peter C Adamson; Nita L Seibel; D Williams Parsons; Y Jae Cho; Katherine Janeway
Journal:  J Natl Cancer Inst       Date:  2017-05-01       Impact factor: 13.506

Review 4.  The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.

Authors:  Erik S Knudsen; Agnieszka K Witkiewicz
Journal:  Trends Cancer       Date:  2017-01

5.  Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4.

Authors:  Wenzhi Jia; Xiaoping Zhao; Li Zhao; Hui Yan; Jiajin Li; Hao Yang; Gang Huang; Jianjun Liu
Journal:  Oncogene       Date:  2018-01-16       Impact factor: 9.867

6.  Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.

Authors:  Rintaro Hashizume; Ali Zhang; Sabine Mueller; Michael D Prados; Rishi R Lulla; Stewart Goldman; Amanda M Saratsis; Andrew P Mazar; Alexander H Stegh; Shi-Yuan Cheng; Craig Horbinski; Daphne A Haas-Kogan; Jann N Sarkaria; Todd Waldman; C David James
Journal:  Neuro Oncol       Date:  2016-07-01       Impact factor: 12.300

Review 7.  Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.

Authors:  Zizhen Ming; Su Yin Lim; Helen Rizos
Journal:  Biomolecules       Date:  2020-10-15

8.  Co-amorphous palbociclib-organic acid systems with increased dissolution rate, enhanced physical stability and equivalent biosafety.

Authors:  Man Zhang; Xinnuo Xiong; Zili Suo; Quan Hou; Na Gan; Peixiao Tang; Xiaohui Ding; Hui Li
Journal:  RSC Adv       Date:  2019-01-29       Impact factor: 4.036

9.  PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.

Authors:  Kelly L Barton; Katherine Misuraca; Francisco Cordero; Elena Dobrikova; Hooney D Min; Matthias Gromeier; David G Kirsch; Oren J Becher
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

10.  Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma.

Authors:  Zhichao Xue; Vivian Wai Yan Lui; Yongshu Li; Lin Jia; Chanping You; Xin Li; Wenying Piao; Hui Yuan; Pek Lan Khong; Kwok Wai Lo; Lydia Wai Ting Cheung; Victor Ho Fan Lee; Anne Wing Mui Lee; Sai Wah Tsao; Chi Man Tsang
Journal:  J Exp Clin Cancer Res       Date:  2020-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.